3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
64
Breast Neoplasms
20
Kidney Neoplasms
19
Gastrointestinal Stromal Tumors
16
Neoplasms
15
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
9
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
7
Brain Neoplasms
7
Colorectal Neoplasms
6
Neuroendocrine Tumors
5
Carcinoma, Hepatocellular
5
Carcinoma
5
Thyroid Neoplasms
4
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Sarcoma
3
Pancreatic Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Kidney Diseases
3
Glioblastoma
3
Esophageal Neoplasms
3
Clear-cell metastatic renal cell carcinoma
3
Astrocytoma
3
Adenoma, Islet Cell
3
Adenocarcinoma, Follicular
3
Interventions
pertuzumab
1
pazopanib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Risk Assessment
1
Radiotherapy
1
Opdualag
1
Nivolumab
1
Injections, Subcutaneous
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Patient Preference
×
Sunitinib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts